WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017172518) DUAL FUNCTION ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/172518    International Application No.:    PCT/US2017/024027
Publication Date: 05.10.2017 International Filing Date: 24.03.2017
IPC:
C07K 16/30 (2006.01), C07K 16/28 (2006.01), A61P 35/00 (2006.01), A61K 47/68 (2017.01)
Applicants: STCUBE, INC. [KR/KR]; #2201, Trade Center Trade Tower, 511 Yeongdong-daero Gangnam-gu Seoul 06164 (KR).
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th St. Austin, Texas 78701 (US)
Inventors: YOO, Stephen S.; (US).
CHUNG, Ezra M.; (US).
KIM, Yong-Soo; (US).
HAN, Kyu Lee; (US).
PARK, Andrew H.; (US).
HUNG, Mien-Chie; (US).
LI, Chia-Wei; (US).
LIM, Seung-Oe; (US)
Agent: BRIVANLOU, Margaret B.; (US)
Priority Data:
62/314,652 29.03.2016 US
62/361,312 12.07.2016 US
Title (EN) DUAL FUNCTION ANTIBODIES SPECIFIC TO GLYCOSYLATED PD-L1 AND METHODS OF USE THEREOF
(FR) ANTICORPS À FONCTION DOUBLE SPÉCIFIQUES DE PD-L1 GLYCOSYLÉE ET LEURS PROCÉDÉS D’UTILISATION
Abstract: front page image
(EN)Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.
(FR)La présente invention décrit des anticorps qui se lient spécifiquement à la PD-L1 glycosylée par rapport à la PD-L1 non glycosylée, la liaison séquencée de PD-L1 à PD-1 et favorisent l’internalisation et la dégradation de PD-L1. Les anticorps qui reconnaissent des épitopes spécifiques sur la protéine PD-L1 glycosylée et qui font preuve de fonctions doubles à la fois bloquant la liaison de PD-L1 à PD-1 et facilitant également l’internalisation de PD-L1 sur les cellules sont décrits. Dans certains aspects, des polypeptides PD-L1 comprenant des résidus d’acides aminés glycosylés aux positions terminales amino et carboxyle du domaine extracellulaire PD-L1 sont également décrits. Des procédés d’utilisation de tels anticorps pour le traitement du cancer, particulièrement du cancer positif PD-L1, sont également décrits.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)